Prognosis in Medical Technology

Melanoma and Pregnancy: What Every Woman Needs to Know About the Risks, Prognosis

... in Baltimore, presented evidence concerning the prognosis for women who become pregnant after surviving ... pregnancy has an adverse influence either on the prognosis of melanoma or the risk of developing melanoma ." prognosis Important when Considering Pregnancy after ...

Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium

... Clinical Testing and Validation, "The 70-gene prognosis profile predicts early metastases in ... in Her2-positive breast cancer by the 70-gene prognosis signature." Presenter: Michael Knauer, MD, ... 12/14/08, 7am - 9am #6034, Poster Session 6: prognosis and Response Predictions - Biomarkers and ...

Abbott's m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award

... HIV-1 assay is intended to monitor disease prognosis and for use as an aid in assessing viral response ... have been shown to be an essential parameter in prognosis and management of HIV infected individuals. ... laboratory markers as an indicator of disease prognosis and for use as an aid in assessing viral response ...

Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients

... ALL patients with MRD following chemotherapy have a significantly worse prognosis than patients without MRD. The primary endpoint of the phase 2 study ... for these patients who are in a disease stage with extremely poor prognosis and for which we lack treatment options except for patients eligible for ...

Vermillion Presents Critical Data From Its OVA1 Clinical Trial

... with the capability of detecting early-stage ovarian cancer, predicting prognosis and recurrence, and identifying women considered at high-risk for the ... with late stage disease where the cancer has spread beyond the ovary. The prognosis is poor in these patients, leading to the high mortality from this ....

Gene Abnormality Found to Predict Childhood Leukemia Relapse

... and in both cancers, there are some children who have a very favorable prognosis and others who are at high risk for treatment failure. By determining the ... CL, Downing JR, and the Children's Oncology Group. Deletion of IKZF1 and prognosis in Acute Lymphoblastic Leukemia. NEJM . Vol. 360, No. 5. St. Jude ...

Agendia's MammaPrint(R) Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer

... potential predictive power. 20 percent of the 144 patients in the poor prognosis signature group achieved a pCR, whereas none of the patients with a good prognosis signature achieved a pCR. After a median follow-up of 25 months, 19 ...

Vermillion Renews Strategic Alliance Agreement With Quest Diagnostics, Inc.

... the capability of such tests to detect early-stage ovarian cancer, predict prognosis and recurrence, and identify women considered at high-risk for the ... with late stage disease where the cancer has spread beyond the ovary. The prognosis is poor in these patients, leading to the high mortality from this ....

Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease

... are clinically important given the rapid progression of PAH and the poor prognosis for these patients," said Professor Ardeschir Ghofrani, MD, Head of ... goal of current treatments is to control symptoms of the disease(2). The prognosis for many PAH patients is similar to that of some advanced cancers, and ...

Vion Pharmaceuticals Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine(R) in Combination with Induction Therapy in Poor Prognosis AML Patients

... with previously untreated acute myelogenous leukemia (AML) and a poor prognosis based on their cytogenetic profile. The Institut Paoli-Calmettes will be ... remission (CR) rate of the combination in AML patients with an unfavorable prognosis based on their cytogenetic profile. Secondary objectives will be to ...

Vermillion's Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease

... in malignant ovarian cysts, may be useful in helping diagnose and predict prognosis of ovarian cancer. Researchers at Vermillion and the University of ... studies are underway to detect early-stage ovarian cancer, predict prognosis and recurrence, and identify women considered at high-risk for the ....

Mayo Clinic Study Shows Drug Could Effectively Treat, Prevent the Spread of Breast Cancer

... case, the study authors feel that 2ME2 has the potential to improve the prognosis of patients with advanced breast cancer. "Targeting metastatic tumors at ... of osteolytic lesions would be desirable therapies and greatly improve the prognosis of patients who have bone metastasis," the authors state. In summary, ...

Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia

... for healthcare professionals to ensure that patients are following their treatment plans in order to help reduce the risk of relapse, because prognosis and outcome can progressively decline with each successive relapse.(4) "Inconsistent compliance with medications is arguably one of the ...

Ipsogen Reports Incorporation of the Genomic Grade in the 2009 St. Gallen International Consensus Meeting on the Primary Treatment of Early Breast Cancer

... and oncologists' decisions along their complex therapeutic path. With more than 70 references already used routinely worldwide for the diagnosis, prognosis and follow-up of thousands of patients with leukemia, Ipsogen is now also targeting breast cancer. As for leukemia, Ipsogen's goal is to provide ...

ThromboGenics' Microplasmin Phase III Program Progressing According to Schedule

... conditions such as macular hole formation, and some forms of macular edema. Vitreomacular adhesion is also potentially associated with a much poorer prognosis in certain major eye indications, including diabetic retinopathy and Age-related Macular Degeneration (AMD). Both of the Phase III studies are ...

Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia

... a significant financial investment in this pioneering effort to develop lestaurtinib for this molecularly targeted patient population with a poor prognosis and few treatment options," said Frank Baldino, Jr., Ph.D., Cephalon founder, chairman and CEO. "Patients with life-threatening diseases need ...

CuraGen Updates CR011-vcMMAE Data at ASCO

... 11,000 patients diagnosed with Stage III or Stage IV disease, and an estimated 8,000 people in the U.S. will die of the disease during 2009. The prognosis for patients with advanced melanoma is poor, and studies have shown that the median survival is less than nine months. About Breast Cancer ...

Neurobiological Technologies' Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program

... is an important finding given the 360,000 patients diagnosed annually with metastatic brain tumors in North America and Europe; moreover, patient prognosis is very poor and the treatment options are very limited. In addition, the NTI-0303 trial showed that use of XERECEPT(R) leads to statistically ...

CuraGen to Present CR011-vcMMAE Data at ASCO

... 11,000 patients diagnosed with Stage III or Stage IV disease, and an estimated 8,000 people in the U.S. will die of the disease during 2009. The prognosis for patients with advanced melanoma is poor, and studies have shown that the median survival is less than nine months. About CuraGen ...

Blanchette Rockefeller Neurosciences Institute and Inverness Medical Innovations to Develop Commercial Test to Detect Early Alzheimer's Disease

... has also obtained an option which, if exercised, will provide Inverness with certain rights to the technology developed for use in the diagnosis, prognosis and monitoring of Alzheimer's disease. "We are very pleased to be working with the world-class memory institute at BRNI, and share in their ...

HIV/AIDS Research Network Recommends Use of Abbott RealTime Viral Load Test for NIH-Sponsored Clinical Trials

... Abbott RealTi m e HIV-1 test is intended for use in conjunction with clinical presentation and other laboratory markers as an indicator of disease prognosis and for use as an aid in assessing viral response to antiretroviral treatment as measured by changes in plasma HIV-1 RNA levels. The assay is not ...

Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology 2009 Meeting

... of cases. Although advances in the surgical management of PVR have improved the ability of surgeons to ultimately reattach the retina, the visual prognosis remains poor, with only 11-25% of patients achieving a visual acuity of 20/100. Presumably this permanent decrease in visual acuity is due, in part, ...

Ipsogen Expands its US Market Presence Through Licensing Agreement With ARUP Laboratories for the Commercialization of JAK2 Molecular Diagnostic Assays

... oncologists' decisions along their complex therapeutic path. With more than 70 references already used routinely worldwide for the diagnosis, prognosis and follow-up of thousands of patients with leukemia, Ipsogen is now also targeting breast cancer. Its initial goal will be to provide diagnostic ...

EAU Position Statement on Screening for Prostate Cancer

... safe methods of cancer surveillance/monitoring without invasive therapy. Invasive therapies should be tailored to patients' needs and the prognosis of cancers diagnosed. - Current screening algorithms are insufficient due to a lack of specificity and lack of selectivity for aggressive ...

FDA Advisory Committee Recommends Approval of Multaq(R) (dronedarone)

... fold) in recent years in the U.S. Atrial fibrillation is a complex disease that increases the risk of stroke up to five-fold, worsens the prognosis of patients with cardiovascular risk factors, and doubles the risk of mortality. There are approximately 2.5 million Americans and 4.5 million people ...

Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas

... said Elliott Grossbard, M.D., executive vice president and chief medical officer of Rigel. In general, patients with PTCL have a poorer prognosis and fewer treatment options than B-cell lymphoma patients. The standard treatment regimen for PTCL, known as CHOP, fails to provide adequate or ...

A First-Line Therapy for Renal Cell Carcinoma that can Increase Overall Survival when Compared with Sutent Would Earn a Higher Patient Share in the United States Than in Europe

... in the first-line setting. Axitinib's data are particularly impressive because patients receiving second-line therapies generally have a poorer prognosis than patients in the first-line setting." About the Report Renal Cell Carcinoma (Metastatic): Axitinib's Improvements in Overall ...

Rosetta Genomics Reports First Ever In-Vivo Efficacy Data for a Systemic MicroRNA Therapeutic for Liver Cancer

... Canada, on February 12th. Liver cancer is the third cause of cancer death globally, affecting over 19,000 patients annually in the US alone. prognosis is extremely grim, with nine out of ten patients dying within 5 years. Sorafenib (Nexavar(R)), the only oral anti-cancer drug currently approved for ...

New England Journal of Medicine Publishes Results From the Landmark ATHENA Trial with Multaq(R) (dronedarone) in Atrial Fibrillation

... fold) in recent years in the US(1). Atrial fibrillation is a complex disease that increases the risk of stroke up to five-fold(3), worsens the prognosis of patients with cardiovascular risk factors(4) and that doubles the risk of mortality(5). The authors' findings, as reported in the New England ...

Cancer Therapy & Research Center at The University of Texas Health Science Center and Oncolytics Biotech(R) Inc. Announce Multi-Trial Clinical Research Collaboration

... underway at this site. "As an NCI-designated cancer center, we give a very high priority to approaches that are likely to significantly improve the prognosis of patients with malignant diseases," said Dr Giles, Deputy Director of the CTRC at UTHSCSA. "As Director of our Institute for Drug Development ...

Transgenomic and Power3 Medical Complete Agreement for Exclusive License of Neurodegenerative Biomarker Test

... and drug targets. Power3 Medical's patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas including ...

ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease

... conditions such as macular hole formation, and some forms of macular edema. Vitreomacular adhesion is also potentially associated with a much poorer prognosis in certain major eye indications, including diabetic retinopathy and Age-related Macular Degeneration (AMD). Dr. Steve Pakola, Chief Medical ...

Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium

... clinical and research experience to date which has shown that the Theros Breast Cancer Index is an excellent test for assessing breast cancer risk prognosis and provides valuable information to physicians treating patients, particularly the most common group of ER- positive, node-negative patients," said ...

Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology

... causing excessive toxicity. High levels of activated Akt (pAkt) are seen frequently in many types of cancer and have been correlated with poor prognosis in patients with soft-tissue sarcoma, gastric, hepatocellular, endometrial, prostate, renal cell, head and neck cancers and hematological ...

Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL

... lost. One deletion that is occasionally seen in CLL patients is the loss of the short arm of chromosome 17 (17p deletion), which may indicate a poor prognosis including significantly inferior survival compared to other CLL patients. Past studies have shown that treatment naive CLL patients were less likely ...

Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL)

... therapy - a final treatment for people who are non-responsive to or cannot tolerate other available therapies for a particular condition and whose prognosis is often poor Arzerra(TM) is the proposed registered trademark to be used in the United States and Europe. To access the latest GSK ...

Studies Examine Quality of Care for Hospitalized Sickle Cell Disease Patients and Effective Methods for Detecting Risk of Stroke in Children With This Disorder

... found that the long-term administration of hydroxyurea in adult patients with sickle cell disease is safe and can improve survival and modify the prognosis of this disease. The beneficial effects of hydroxyurea suggest that doctors should consider expanding the use of hydroxyurea to all patients with ...

Medarex Announces Initiation of Phase 1b Clinical Development Program with MDX-1106 for the Treatment of Cancer

... and chronic infectious disease settings, as well as a strong correlation between increased PD-L1 expression on tumors and a negative survival prognosis in cancer patients. Preclinical studies indicate that antibodies targeting the PD-1 signaling pathway reinvigorate antigen-specific T-cell responses ...

Ipsogen Launches a New Test to Determine Tumor HER2 Status and Guide Herceptin(R) Prescription in Breast Cancer

... and oncologists decisions along their complex therapeutic path. With more than 60 tests already used routinely worldwide for the diagnosis, prognosis and follow-up of thousands of patients with leukemia, Ipsogen is now also targeting breast cancer. Its initial goal will be to provide diagnostic ...

Celladon Announces Presentation of Clinical Data From First-in-Human MYDICAR(R) Trial for Advanced Heart Failure at American Heart Association Scientific Sessions

... and indirect costs to the healthcare system in 2008 of $35 billion. Despite important therapeutic advances in pharmacologic and device therapies, the prognosis of heart failure patients remains poor. Access to nonpharmacologic therapies, such as heart transplantation and the use of mechanical assist devices, ...